Key result
Targeting macrophage ferroptosis emerges as a novel therapeutic strategy to stabilize atherosclerotic plaques.
Why the study?
Current pharmacologic treatment of atherosclerosis relies primarily on lipid-lowering agents, which remain deficient and are associated with adverse effects. Meanwhile, the specific mechanisms of macrophage ferroptosis in plaque instability and potential therapeutic strategies targeting this process remain to be addressed.
Answers are grounded in this paper and cite their sources.
This narrative review highlights macrophage ferroptosis as a key driver of atherosclerotic plaque progression and instability, summarizing potential pharmacological strategies targeting this pathway.
Atherosclerosis is the underlying cause of many cardiovascular diseases, and macrophages play a pivotal role in its intricate landscape, significantly regulating inflammation, lipid metabolism, and iron metabolism. Ferroptosis is an iron-dependent form of regulated cell death driven by lipid peroxidation, and its process is related to macrophage function in atherosclerosis. During atherosclerosis, macrophages contribute to the removal of harmful substances such as lipids and inhibit early development. However, macrophage ferroptosis promotes inflammatory progression, facilitates foam cell and necrotic core formation, promotes calcification, and increases plaque instability. This review first summarizes macrophage heterogeneity in atherosclerosis, then integrates their roles in lipid handling and iron metabolism, and finally focuses on how ferroptosis shapes plaque inflammation, necrotic core formation, calcification, and instability. Currently, the pharmacologic treatment of atherosclerosis is based on lipid-lowering agents, but it remains deficient. Therefore, this review encompasses a variety of potential pharmacological treatments, including organic compounds, natural plant extracts and derivatives, and compound formulations, which can inhibit macrophage ferroptosis and may constitute a novel approach for atherosclerosis treatment. Taken together, this review provides a breakthrough strategy for treating atherosclerosis and establishes a navigational pathway for future therapeutic interventions by targeting macrophage ferroptosis.
No takes yet. Share an insight, caveat, or question.
Shi et al. (2026) conducted a review in Atherosclerosis. Pharmacological agents targeting macrophage ferroptosis (organic compounds, natural plant extracts and derivatives, and compound formulations) was evaluated. Macrophage ferroptosis promotes plaque inflammation, necrotic core formation, calcification, and instability in atherosclerosis, making it a promising novel target for pharmacological intervention.
Synapse has enriched 10 related papers. Consider them for comparative context: